Yale Podnos Sells 23,451 Shares of Oncology Institute (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) insider Yale Podnos sold 23,451 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $5.38, for a total value of $126,166.38. Following the completion of the transaction, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. This trade represents a 8.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oncology Institute Stock Down 5.6%

Shares of TOI stock opened at $4.68 on Thursday. The stock has a market cap of $462.57 million, a PE ratio of -12.65 and a beta of 0.37. The Oncology Institute, Inc. has a 52-week low of $2.02 and a 52-week high of $5.57. The business has a 50-day simple moving average of $3.90 and a 200-day simple moving average of $3.42.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The business had revenue of $147.44 million for the quarter, compared to analysts’ expectations of $142.10 million. Sell-side analysts anticipate that The Oncology Institute, Inc. will post -0.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of Oncology Institute by 36.6% during the first quarter. Bank of America Corp DE now owns 63,439 shares of the company’s stock valued at $195,000 after acquiring an additional 16,991 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Oncology Institute during the first quarter valued at approximately $154,000. Royal Bank of Canada raised its holdings in shares of Oncology Institute by 335.9% during the first quarter. Royal Bank of Canada now owns 22,257 shares of the company’s stock valued at $68,000 after acquiring an additional 17,151 shares during the last quarter. FourWorld Capital Management LLC raised its holdings in shares of Oncology Institute by 30.4% during the first quarter. FourWorld Capital Management LLC now owns 499,196 shares of the company’s stock valued at $1,533,000 after acquiring an additional 116,496 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Oncology Institute by 25.1% during the first quarter. Renaissance Technologies LLC now owns 902,809 shares of the company’s stock valued at $2,772,000 after acquiring an additional 180,909 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TOI shares. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price target on shares of Oncology Institute in a report on Monday, March 9th. B. Riley Financial lifted their target price on shares of Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, March 13th. BTIG Research boosted their target price on shares of Oncology Institute from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.25.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.